Key Highlights
- Phoslock Environmental Technologies (ASX:PET) received AUD 1.132 million in September-quarter sales receipts.
- Net operating cash outflow fell to AUD 21,000 from AUD 952,000 a year earlier.
- Sales Volume reached 275 tonnes, up from both the June quarter and the prior September quarter.
- The company paused Manufacturing at Changxing and began a bulk trial of its Phoslock 10 formulation.
Phoslock Environmental Technologies (ASX:PET) develops and supplies products used in water treatment. Its 22 October 2026 Quarterly Report recorded an increase in sales volumes and receipts, a smaller operating cash outflow and a manufacturing pause at its Changxing Facility in China. The update also covered work on several formulations and testing at a pond in Changzhou.
September receipts and cash movements
Sales receipts increased from AUD 562,000 a year earlier and AUD 501,000 in the June 2026 quarter. The company attributed the reduction in net operating cash outflow to the increase in sales receipts and lower net operating outlays. Those outlays totalled AUD 1.153 million, including AUD 36,000 in legal fees, and reflected AUD 27,000 in insurance reimbursements and an AUD 116,000 refund of excess US Import duties paid in the previous year. Net investing cash outflow was AUD 30,000, and the company reported no financing cash flow. Cash fell by AUD 90,000 after foreign exchange movements to AUD 3.436 million at quarter end.
Sales mix and the Changxing pause
Phoslock sold 275 tonnes in the quarter, up from 251 tonnes in September 2025 and 189 tonnes in June 2026. Brazil accounted for 61% of the reported volume and Australia for 24%. Quarterly production totalled 457 tonnes, taking year-to-date output to 1,524 tonnes. The company held 1,848 tonnes of product at quarter end, including 983 tonnes in China. It paused production at the end of August after inventories in Changxing reached the site’s available storage capacity. It also cited the deferral of several European projects to the first quarter of 2027.
Laboratory testing and the Phoslock 10 trial
The company extended its laboratory work to formulations containing 15% and 20% lanthanum. Testing used saline, alkaline and pond water as well as pure water, and the company filed a Patent application connected with its development work. The bulk trial of its separate 10% formulation followed a search for a suitable site. The first site is a small pond in Jintan, Changzhou, where the company reported applying 700 kilograms of product in the week of the announcement. It planned to sample and analyse water and sediment over the following months.
Manufacturing and trial plans
Phoslock expected manufacturing to resume in the months following the October report and identified the pause as an opportunity to conduct further bulk production runs for new products. Separately, it was identifying suitable sites for additional bulk trials in the United States, Europe and Australia. Those plans accompanied the Jintan trial, where the initial application had already taken place. The report also noted that the company’s quarterly cash flows can vary substantially from period to period.
Phoslock also disclosed that a Federal Court Shareholder class action remained ongoing. The company described the matter as largely at the discovery stage and said formal court proceedings might not take place before 2027. It did not report any finding or outcome in the quarterly update.
The quarter closed with higher sales tonnage, an inventory balance of 1,848 tonnes and a manufacturing pause at Changxing. The operational work set out in the filing included monitoring the first bulk trial, finding sites for further trials and preparing for a restart of regular manufacturing.






Please wait processing your request...